Diffuse Large B Cell Lymphoma: Five Factors For A Prognosis

Diffuse large B cell lymphoma prognosis is contingent upon several factors, and can be determined by using a well-established and reliably predictive model known as the Revised International Non-Hodgkin's Lymphoma Prognostic Index (IPI or R-IPI). In order for this to be applicable, the patient must have been diagnosed with DLBCL and be treated with Rituximab-based combination chemotherapy, namely R-CHOP.

The Index uses five factors for a prognosis, assigns a single point to each factor if true, then takes the sum total and uses it to determine a survival rate percentage.

Prognosis Factors

  • AGE: Patients over the age of 60 add one point.
  • SERUM LDH: If LDH (lactate dehydrogenase) levels are elevated, add one point.
  • PERFORMANCE STATUS: If the patient's performance status is determined to be between 2 and 4 add one point.
  • DISEASE STAGE: If the patient is diagnosed at stage III or stage IV, add one point.
  • EXTRANODAL INVOLVEMENT: If the patient's lymphoma involves more than one extranodal site (such as bone, liver, spleen, or bone marrow), add one point.

So a patient can have between 0 and 5 points. Here's what those totals mean for a prognosis:

0 points

  • Prognosis: Very good
  • Predicted 4-year progression-free survival: 94 percent
  • Overall survival: 94 percent

1-2 points

  • Prognosis: Good.
  • Predicted 4-year progression-free survival: 80 percent
  • Overall survival: 79 percent

3-5 points

  • Prognosis: Poor
  • Predicted 4-year progression-free survival:53 percent
  • Overall survival: 55 percent

Conclusion

This index has shown to be a reasonably predictive model in determining a prognosis; however, it will not hold true for every single diagnosed and treated patient.

Related Reading

Photo: Pexels

b cell lymphoma tretment

More Articles

More Articles

In T cell lymphoma, T lymphocytes, which are an essential part of the body's immune response, become malignant. T cell lymphomas account for about...

Lymphomatoid Papulosis (LyP) is a rare skin disorder that involves cancerous looking skin lesions. It is more than a skin condition; it is the...

In non-Hodgkin's lymphoma, you have your B-cell lymphomas and you have your T-cell lymphomas.

Why B...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is a relatively rare B-cell subtype of non-Hodgkin'...

T-Cell Lymphoblastic Lymphoma (T-LBL) is a very rare subtype of non-Hodgkin's lymphoma. It tends to develop in...

In general, a diagnosis of T-cell lymphoma denotes a poorer prognosis than a diagnosis of B-cell lymphoma. One of...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

The term NK T cell lymphoma refers to one of two subtypes of lymphoma that affect the NK (Natural Killer)...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...